Literature DB >> 15670187

Substitutions in the CYP21A2 promoter explain the simple-virilizing form of 21-hydroxylase deficiency in patients harbouring a P30L mutation.

Rogério S Araujo1, Ana Elisa C Billerbeck, Guiomar Madureira, Berenice B Mendonca, Tânia A S S Bachega.   

Abstract

The classical and nonclassical phenotypes of 21-hydroxylase deficiency represent a continuous spectrum of the impairment of 21-hydroxylase activity due to mutations between the CYP21A2 gene. These mutations occur mainly by microconversion in the homologous nonfunctional CYP21A1P gene. The P30L mutation is associated with the nonclassical form, and it reduces the activity to 30-40% of the normal enzyme. We have described three female patients exhibiting a simple virilizing phenotype and bearing the P30L mutation in compound heterozygosis with a severe mutation. To identify additional mutations causing this phenotype, the promoter region was sequenced and four mutations were identified: -126C --> T, -113G --> A, -110T --> C and -103 A --> G. These substitutions are normally present in the promoter region of the pseudogene and in vitro studies demonstrated that they reduced the transcriptional activity fivefold. They might have been converted to the CYP21A2 promoter together with the P30L mutation in these patients. Therefore, these substitutions in synergism with the P30L mutation might decrease the enzyme activity resulting in a more severe phenotype, and a DNA sequence of -167 bases of the CYP21A2 gene should be performed in patients with 21-hydroxylase deficiency in whom the phenotype is more severe than predicted by the genotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15670187     DOI: 10.1111/j.1365-2265.2005.02184.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

Review 1.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

2.  Molecular genetic analysis of CYP21A2 gene in patients with congenital adrenal hyperplasia.

Authors:  Eunice Marumudi; Arundhati Sharma; Bindu Kulshreshtha; Rajesh Khadgawat; Madan L Khurana; Ariachery C Ammini
Journal:  Indian J Endocrinol Metab       Date:  2012-05

Review 3.  Molecular Diagnosis of Steroid 21-Hydroxylase Deficiency: A Practical Approach.

Authors:  María Arriba; Begoña Ezquieta
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-29       Impact factor: 5.555

4.  Clinical profile and inheritance pattern of CYP21A2 gene mutations in patients with classical congenital adrenal hyperplasia from 10 families.

Authors:  Sarita Yadav; Shweta Birla; Eunice Marumudi; Arundhati Sharma; Rajesh Khadgawat; M L Khurana; A C Ammini
Journal:  Indian J Endocrinol Metab       Date:  2015 Sep-Oct

5.  p.Gln318X and p.Val281Leu as the Major Variants of CYP21A2 Gene in Children with Idiopathic Premature Pubarche.

Authors:  Mahdieh Soveizi; Nejat Mahdieh; Aria Setoodeh; Fatemeh Sayarifard; Farzaneh Abbasi; Himangshu S Bose; Bahareh Rabbani; Ali Rabbani
Journal:  Int J Endocrinol       Date:  2020-05-15       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.